Designing Longevity
Skip to main content
Compounded GLP-1

Mochi Health

Program terms need a fresh check

Edited by Designing Longevity Editorial · public sources checked October 9, 2026

Current program terms need a fresh check. Request a written care and medication quote. Earlier public-record dates are shown below.

Program terms need a fresh check. Ask Mochi Health for a written quote covering care, medication, billing and cancellation. The earlier broad provider rating remains withdrawn. The earlier numeric rating was withdrawn because its source basis included incorrect chronology, an unsupported separate notice, and outdated accreditation facts. A full six-dimension reassessment has not been completed. The dated public-record details remain below.

Reviews of individual programs

Program reviews cover their own costs, terms and support. The program-terms checklist applies to the named care program, not every service offered by this company.

Mochi Health GLP-1 program review

Program costs and payment terms

Public program terms checked November 9, 2026. Public standard one-month self-pay membership, conditional first-month promotion, listed medication forms and starting prices, representative compounded injection dose tables, insurance assistance, lab starting price, and published cancellation/refund/shipping terms checked November 9, 2026 UTC. Covered with Mochi is a separate plan. No checkout eligibility, patient quote, pharmacy assignment, clinical care, credentials or clinical suitability was verified.

Compounded medicine: not FDA-approvedSome documented offers use compounded medication. FDA approval of a brand-name medicine does not extend to a compounded formulation. FDA compounding information

Membership
$79/month on the standard monthly plan; medication extra. Public introductory offers differ, so confirm your first charge at checkout.
Insurance
Insurance support is conditional on the plan and medication. Mochi says its team can assist with prior authorization, but coverage and medication cost depend on the insurer and plan. Covered with Mochi is a separate commercial-insurance membership with eligibility and visit cost sharing; it does not include medication. No coverage or cost is guaranteed.
Oral Wegovy
Current availability needs a fresh check.
Membership prepayment
Prepaid membership equivalents: $69/month for 3 months ($207 upfront), $59/month for 6 months ($354 upfront), $49/month for 12 months ($588 upfront). Medication is extra. Confirm how any introductory offer applies, the amount charged now, the recurring amount and the next renewal date before paying.
Cancel before renewal
Membership auto-renews. Cancel in the account or by phone before renewal; cancellation takes effect at the end of the current term. Email cancellation requests are not accepted.
Intro offer and refunds
The public one-month self-pay card offers $0 for the first care month to eligible new subscribers in some states, then $79 monthly. This conditional promotion is not a universal introductory amount. Medication and lab panels cost extra. Partially used membership periods generally are not refunded, subject to stated discretion; prescription medicine has separate refund rules.
Stopping medication
BBB warns that membership and medication subscriptions are separate and need separate cancellation. Mochi's September terms say ending paid membership automatically cancels medication subscriptions that require it, but other medication subscriptions continue. Confirm each subscription is canceled and retain confirmation before its next renewal or pharmacy order.
Outside pharmacy orders
Mochi uses pharmacy partners, and the patient account shows the upcoming medication order price. The FAQ says shipping is included in medication prices, but September 22 terms allow applicable shipping charges, taxes and fees on medication subscriptions. The exact pharmacy, state and order may affect the final charge; check the total before payment. Lab panels are advertised from $26, not as a complete lab bill.

Advertised compounded injection examples

These representative medication ranges depend on prescribed dose, state and pharmacy. Membership is separate. The total adds standard monthly membership; it excludes diagnostics and any other charges. It is not a personal quote, a guaranteed maximum or a dosing recommendation.

MedicationMedication per monthWith standard monthly membership
Compounded semaglutideCompounded medicine: not FDA-approved$60 to $99$139 to $178
Compounded tirzepatideCompounded medicine: not FDA-approved$90 to $199$169 to $278
  • Public dose-tier examples for compounded semaglutide injection cover listed weekly doses 0.22-2.67 mg. Representative; varies by state, pharmacy and prescribed dose. The listed dose table is an advertised example, not an upper bound on every patient's bill. Terms also permit applicable taxes, shipping and fees; the exact order total is unknown. Medication only; membership billed separately. Provider prescription required. Compounded product is not FDA-approved or evaluated for safety, effectiveness or quality.
  • Public dose-tier examples for compounded tirzepatide injection cover listed weekly doses 2.2-16.6 mg. Representative; varies by state, pharmacy and prescribed dose. The listed dose table is an advertised example, not an upper bound on every patient's bill. Terms also permit applicable taxes, shipping and fees; the exact order total is unknown. Medication only; membership billed separately. Provider prescription required. Compounded product is not FDA-approved or evaluated for safety, effectiveness or quality.

Compounded medications are not FDA-approved or evaluated by the FDA for safety, effectiveness or quality. Ask which pharmacy will fill your prescription and get its formulation and total in writing before paying.

Designing Longevity is a founder-led editorial publication. Our content is not medically reviewed.

Public records on this page were checked October 9, 2026. The earlier rating was withdrawn; this is not a medical or pharmacy inspection.

Read the October 9 public-record correction and earlier profile (October 9, 2026)

This record keeps its original check dates. The program-terms checklist above covers costs, billing and advertised support for the named care program.

Our take

The Washington action against Aequita is a documented historical pharmacy concern, while the current dispensing pharmacy and resolution of that state restriction were not verified. now lists Mochi as accredited with an A grade; that does not measure sterile-compounding quality. We have withdrawn our earlier numeric score until a complete review can be done.

Pros

  • accredited since August 24, 2026, with an A grade at this public-source check
  • Large review sample at this public-source check

Cons

  • Historical Washington sterile-compounding enforcement against Aequita Pharmacy, linked to Mochi in court records
  • Two manufacturer civil cases with proceedings in September 2026; the allegations remain unproven
  • Current pharmacy assignment and Washington order resolution were not verified

Pricing

$79/month on the standard monthly plan; medication extra. Public introductory offers differ, so confirm your first charge at checkout.

Turnaround

Confirm current intake and fulfillment timing with Mochi

States served

Not verified

Public sources checked

October 9, 2026

What the public records show

The earlier numeric rating was withdrawn because its source basis included incorrect chronology, an unsupported separate notice, and outdated accreditation facts. A full six-dimension reassessment has not been completed.

  • Washington issues Limited Stop Service against Aequita Pharmacy

    Washington issued a Limited Stop Service against Aequita Pharmacy LLC. The notice alleged deficient sterile-compounding practices, including untrained and unqualified staff and inadequate supervision. It restricted compounding and dispensing, delivery, or distribution of compounded products in Washington until resolved. The current resolution was not verified.

    Primary source
  • Washington announces July 2025 agreed order with Aequita Pharmacy

    Washington announced that it and Aequita had entered an agreed order in July 2025. It imposed sterile-compounding restrictions, monitoring, quarterly reports, and staff education. The state said March to May inspections found deficiencies creating immediate jeopardy to patient safety. The precise signing day was not specified in the announcement.

    Primary source
  • Aequita surrenders North Carolina nonresident pharmacy permit for cause

    Aequita surrendered its North Carolina nonresident pharmacy permit for cause. The state order says it may not dispense or compound for North Carolina patients unless the permit is reinstated.

    Primary source
  • Court narrows conspiracy theory in Lilly case against Mochi entities

    A federal court dismissed Lilly's false-advertising conspiracy theory against Mochi Medical and Aequita entities without leave to amend, while allowing an unfair-competition conspiracy theory against Aequita entities to proceed. Direct unfair-competition and Lanham Act claims against Mochi Health remained. This pleading-stage ruling does not establish the truth of the allegations.

    Primary source
  • Novo Nordisk files civil case against Mochi entities

    Novo Nordisk filed a civil case concerning compounded semaglutide marketing and alleged corporate practice of medicine. A September 2026 discovery order shows continued proceedings then, not a final ruling on the allegations.

    Primary source
  • BBB accreditation and grade

    BBB lists Mochi as accredited since August 24, 2026 with an A grade and 1,418 complaints. This is a complaint-handling signal, not a clinical-quality finding.

    Primary source
  • Trustpilot public reviews

    Trustpilot displayed 4.5/5 across 19,304 reviews at this check. Ratings can change and do not establish pharmacy quality.

    Primary source

Public reviews

What we found across third-party review platforms. These are external sentiment signals, not our scoring inputs.

Better Business Bureau

Accredited since August 24, 2026; A grade; 1,418 complaints shown. accreditation does not certify clinical or pharmacy quality.

Captured October 9, 2026Source

Trustpilot

4.5(19,304)

Public consumer rating and count at the October 2026 check; this is experience feedback, not a clinical safety measure.

Captured October 9, 2026Source

Regulatory & legal history

FDA enforcement actions, manufacturer lawsuits, recalls, and other notable events on the public record.

  1. State Board ActionMarch 13, 2025

    Washington issued a Limited Stop Service against Aequita Pharmacy LLC. The notice alleged deficient sterile-compounding practices, including untrained and unqualified staff and inadequate supervision. It restricted compounding and dispensing, delivery, or distribution of products in Washington until resolved. The current resolution was not verified.

    Source
  2. State Board ActionMarch 17, 2025

    Aequita surrendered its North Carolina nonresident pharmacy permit for cause. The state order says it may not dispense or compound for North Carolina patients unless the permit is reinstated.

    Source
  3. Lawsuit FiledApril 23, 2025

    Lilly filed a civil case concerning marketing and alleged corporate practice of medicine. These are allegations, not findings. A September 2026 order shows the case was still proceeding then.

    Source
  4. Lawsuit FiledAugust 4, 2025

    Novo Nordisk filed a civil case concerning marketing and alleged corporate practice of medicine. A September 2026 discovery order shows continued proceedings then, not a final ruling on the allegations.

    Source
  5. State Board ActionSeptember 22, 2025

    Washington announced that it and Aequita had entered an agreed order in July 2025. It imposed sterile-compounding restrictions, monitoring, quarterly reports, and staff education. The state said March to May inspections found deficiencies creating immediate jeopardy to patient safety. The precise signing day was not specified in the announcement.

    Source
  6. Notable EventSeptember 8, 2026

    A federal court dismissed Lilly's false-advertising conspiracy theory against Mochi Medical and Aequita entities without leave to amend, while allowing an unfair-competition conspiracy theory against Aequita entities to proceed. Direct unfair-competition and Lanham Act claims against Mochi Health remained. This pleading-stage ruling does not establish the truth of the allegations.

    Source

Accreditations

BBB lists Mochi as an accredited business since August 2026. We did not verify a current pharmacy-specific accreditation in this public-source check; BBB accreditation does not assess medication quality.

Frequently asked

What does Mochi Health charge for membership?

$79/month on the standard monthly plan; medication extra. Public introductory offers differ, so confirm your first charge at checkout.

Does Mochi Health accept insurance?

Insurance support is conditional on the plan and medication. Mochi says its team can assist with prior authorization, but coverage and medication cost depend on the insurer and plan. Covered with Mochi is a separate commercial-insurance membership with eligibility and visit cost sharing; it does not include medication. No coverage or cost is guaranteed.

What happened with Aequita Pharmacy?

Washington issued Aequita a Limited Stop Service on March 13, 2025, then announced a July 2025 agreed order with sterile-compounding restrictions and monitoring. The state said inspections found deficiencies creating immediate jeopardy to patient safety. We did not verify a separate later escalation notice, the current Washington order status, or the pharmacy filling current Mochi prescriptions.

Is Mochi Health under a lawsuit?

Eli Lilly and Novo Nordisk filed separate civil suits. Court orders from September 2026 show proceedings in both. The allegations are disputed and neither order establishes liability or the cases' final outcomes.

Does the current rating include a medical review?

No. We withdrew our earlier numeric score after finding errors in its source basis. This update checks public records, business complaints, and consumer reviews. It does not inspect a pharmacy, assess your prescription, or verify the pharmacy assigned to a new patient.

Update history

Every meaningful change to this profile, with a date stamp. We don't silently re-score.

  1. May 1, 2026

    Original Mochi profile published. Its rating and source basis were subsequently withdrawn; see the correction below.

  2. October 9, 2026

    Corrected the Washington action from February 2026 to March 2025, distinguished inspection findings from a separately titled notice, removed unverified whistleblower details as regulatory findings, updated and records, and withdrew the earlier numeric score pending a complete reassessment.

Edited by Designing Longevity Editorial. Earlier profile checked October 9, 2026.

Spot something out of date or wrong? Let us know and we'll re-check.

Back to all providers